| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/JCM.42.7.3117-3119.2004 |
| P8608 | Fatcat ID | release_lxrx5r7rznbihabfsiwgqi7huu |
| P932 | PMC publication ID | 446304 |
| P698 | PubMed publication ID | 15243069 |
| P5875 | ResearchGate publication ID | 8466310 |
| P50 | author | Daniel J. Diekema | Q43292463 |
| Michael A. Pfaller | Q62070176 | ||
| P2093 | author name string | C Rice | |
| L Boyken | |||
| R J Hollis | |||
| S A Messer | |||
| S Tendolkar | |||
| P2860 | cites work | Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 |
| In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) | Q28379217 | ||
| Evaluation of endpoints for antifungal susceptibility determinations with LY303366. | Q33693384 | ||
| Caspofungin | Q34199905 | ||
| Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility | Q34202154 | ||
| Caspofungin acetate: an antifungal agent | Q34306508 | ||
| Caspofungin: the first representative of a new antifungal class. | Q35077417 | ||
| In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis | Q35091285 | ||
| Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus | Q35102477 | ||
| Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. | Q35138937 | ||
| Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies | Q35512289 | ||
| Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species | Q37157546 | ||
| In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. | Q39731811 | ||
| Caspofungin activity against clinical isolates of fluconazole-resistant Candida | Q40404311 | ||
| In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions | Q42547763 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3117-3119 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates | |
| P478 | volume | 42 |
| Q42104395 | Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. |
| Q42846025 | Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. |
| Q41835779 | Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata |
| Q42090519 | Assessment of the paradoxical effect of caspofungin in therapy of candidiasis |
| Q34237335 | Canadian clinical practice guidelines for invasive candidiasis in adults |
| Q30445376 | Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program |
| Q41849134 | Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration |
| Q33935389 | Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome |
| Q38586680 | Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes |
| Q36257157 | Caspofungin: a review of its use in the treatment of fungal infections |
| Q36925967 | Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance |
| Q39763435 | Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. |
| Q42561331 | Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. |
| Q36845482 | Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. |
| Q30435993 | Determination of Echinocandin MICs for Candida species in less than 8 hours: comparison of the rapid susceptibility assay with the Clinical and Laboratory Standards Institute's broth microdilution assay |
| Q36441524 | Echinocandin antifungals: review and update |
| Q28264860 | Echinocandins in the management of invasive fungal infections, Part 2 |
| Q24537282 | Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q37029222 | Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q42131206 | Flow cytometry susceptibility testing for the antifungal caspofungin |
| Q36497888 | Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. |
| Q35714132 | Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. |
| Q35073614 | Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. |
| Q58033533 | Glucan Synthase Inhibitors |
| Q24538858 | In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole |
| Q36538739 | In vitro and in vivo antifungal activities of T-2307, a novel arylamidine |
| Q42222929 | In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance |
| Q42221406 | In vitro susceptibility of Candida isolates from organ transplant recipients to newer antifungals. |
| Q41810114 | In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. |
| Q35690723 | Kodamaea ohmeri isolates from patients in a university hospital: identification, antifungal susceptibility, and pulsed-field gel electrophoresis analysis |
| Q36867925 | Micafungin activity against Candida albicans with diverse azole resistance phenotypes |
| Q36899118 | Molecular phylogenetic analysis of a geographically and temporally matched set of Candida albicans isolates from humans and nonmigratory wildlife in central Illinois |
| Q34510707 | Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility |
| Q35912243 | Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. |
| Q35878982 | Role for cell density in antifungal drug resistance in Candida albicans biofilms |
| Q42051327 | Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study |
| Q36095050 | The Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole |
| Q36742397 | The echinocandins |
| Q37255172 | Treatment of invasive candidiasis in immunocompromised pediatric patients |
| Q36898200 | Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study |
| Q42929579 | Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. |
Search more.